
    
      The primary study objective is to evaluate recurrence/metastasis free survival at 12 months
      with postoperative adjuvant treatment incorporating gemcitabine plus cisplatin chemotherapy
      followed by chemoradiation with gemcitabine followed by maintenance chemotherapy with
      gemcitabine.
    
  